Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. (2021)

Peer-Reviewed Study · Suganthapriya Elayapillai; Satishkumar Ramraj; Doris Mangiaracina Benbrook et al. · January 2021

Suganthapriya Elayapillai et al., 2021-01: Elayapillai et al. test mebendazole in cisplatin-resistant ovarian cancer patient-derived xenografts and orthotopic models, finding growth inhibition and reduced tumour establishment.

Mebendazole inhibited growth of ovarian cancer cell cultures at nanomolar concentrations and PDXs at doses up to 50 mg/kg, and reduced orthotopic tumor establishment at 50 mg/kg.

Suganthapriya Elayapillai et al., 2021-01: Elayapillai et al. test mebendazole in cisplatin-resistant ovarian cancer patient-derived xenografts and orthotopic models, finding growth inhibition and reduced tumour establishment. Study type: ovarian cancer cell lines plus patient-derived xenografts (PDX-0003 p53-null, PDX-0030 p53-positive) and an orthotopic MES-OV model. N: cohorts of 5-7 mice per dose group per the full text. Country: USA (University of Oklahoma). Dose: 10, 25 and 50 mg/kg by oral gavage in the PDX work. Funder: US NIH P30 CA225520 and U54 GM104938. Declared conflicts: 'The authors declare no conflict of interest.' Comparator: vehicle, and PRIMA-1MET alone and in combination. The paper opens by noting that mebendazole is being used off-prescription on the basis of social-media accounts, and frames itself as a controlled test.